The synthesis of a new series of diarylureas and amides having a 1-substituted-3-(3-chloro-5-methoxyphenyl)-4-pyridinylpyrazole scaffold is reported here. The in vitro antiproliferative activities of these diaryl derivatives against human melanoma cell line A375 were tested and the effect of substituents on the phenyl ring was investigated. Most of the newly synthesized compounds generally showed superior or similiar activity against A375 to Sorafenib. Among these compounds, IId, IIg and IIh showed excellent activity against A375 compared to Sorafenib.
Introduction
Melanoma, the most aggressive form of skin cancer, is the fastest growing cancer in the United States. 1, 2 Early stage melanoma can be cured surgically. However, melanoma metastasizing to major organs (stage IV) is virtually incurable. 2 Patients with disseminated melanoma have a median survival time of less than a year, and the estimated 5-years survival rate is less than 15%. 2, 3 With the rapid incidence of melanoma in the United States and other developed countries, there is an urgent need to develop more effective drugs. [4] [5] [6] Recently, Sorafenib, as well as other diarylureas, have been evaluated as potent and selective antiproliferative agents for the treatment of melanoma. [7] [8] [9] [10] [11] [12] The promising results have encouraged many research groups to investigate diarylurea scaffolds to develop new derivatives for the treatment of cancer. [13] [14] [15] [16] [17] Accordingly, we have synthesized a new series of diaryl ureas, and reported their antiproliferative activity against A375 human melanoma cell line.
In this work, we investigated the effect of replacing the 2-(methylaminocarbonyl)pyridine-4-yloxy group in Sorafenib with a 3-(3-chloro-5-methoxyphenyl)-4-pyridinyl-pyrazole moiety on the antiproliferative activity. The effect of substitution at the other phenylurea ring is also investigated by using the different substituents R.
Results and Discussion
Chemistry. 1,3,4-Triarylpyrazole derivatives (Ia-f and IIa-e) with urea moiety at the terminal part were prepared according to the sequence of reactions shown in Scheme 1. Heating 3,5-dichlorobenzoic acid (1) with two molecular equivalents of sodium methoxide in hexamethylphosphoramide (HMPA) gave 3-chloro-5-methoxybenzoic acid (2), which upon esterification with methanol in the presence of acetyl chloride afforded the corresponding methyl ester 3. The pyridyl derivative 4 was obtained by treatment of 3 with 4-picoline in THF in the presence of lithium bis(trimethylsilyl)amide (LHMDS). 3,4-Diarylpyrazole derivative 5 was obtained by treatment of 4 with dimethylformamide dimethyl acetal (DMF-DMA), and subsequent treatment with hydrazine monohydrate. 1,3,4-Triarylpyrazole derivative 7 with amino group was prepared through N-arylation of 5 using 1-iodo-4-nitrobenzene in DMSO in the presence of anhydrous K2CO3, and subsequent reduction of the nitro group of 6 using stannous chloride. Interaction of the amino group with phenylisocyanate derivatives in THF afforded the corresponding urea derivatives (Ia-f). Demethylation of the methoxy group of compounds Ia-f using BBr3 afforded the corresponding hydroxy derivatives (IIa-e).
The synthesis of Ig-i and IIf-h with amide moiety at the terminal part was carried out by the same procedure described for synthesis of urea derivatives (Ia-f and IIa-e). Benzoic acid derivatives were used instead of phenylisocyanate derivatives for acylation of amino group of 7 in DMF in the presence of HOBt and EDCI to afford Ig-i. Demethylation of the methoxy group in order to obtain the corresponding hydroxy derivatives (IIf-h) was achieved by the same method described for preparation of IIa-e.
In vitro activity. The antiproliferative activity of the newly synthesized compounds against A375 human melanoma cell line was examined. The ability of these compounds to inhibit the growth of A375 cell line is summarized in Tables 1 and 2 . Sorafenib was selected as a reference standard, because it has been extensively used in clinical trials for melanoma. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Regarding the terminal substituents on the phenyl ring of the tail, it was found that compounds Ih, IIf, IIg, and IIh having amide moiety were more potent than compounds Ib, IIa, IIb, and IIc having urea moiety. As to the substituents on the chlorophenyl ring, compounds IIb, IId, IIe, IIf, IIg, and IIh with hydroxyl group showed higher antiproliferative activity in comparison with the corresponding methoxy derivatives Ib, Id, Ie, Ig, Ih, and Ii. This indicates that the more polar substituent at this position is preferable. Most of the newly synthesized compounds generally showed superior or similiar activity against A375 to Sorafenib. Among these compounds, IId, IIg and IIh showed excellent activity against A375 compared to Sorafenib.
Experimental Section
Melting points (mp) were determined on a Walden Precision Apparatus Electrothermal 9300 apparatus and were uncorrected. 1 H-NMR spectral data were recorded using a Gemini 300 spectrometer. Mass spectra were recorded on a Waters 3100 Mass Detecter.
A375P Cell culture and anti-proliferative activity of tested compound on A375P. A375P cells were purchased from American Type Culture Collection (ATCC, Rockville, MD, US) and maintained in a DMEM (Welgene, Daegu, Korea) supplemented with 10% FBS (Welgene) and 1% penicillin/streptomycin (Welene) in a humidified atmosphere with 5% CO2 at 37 o C. A375P cells were taken from culture substrate with 0.05% trypsin-0.02% EDTA and plated at a density of 5 × 10 3 cells/ well in 96 well plates and then incubated at 37 o C for 24 hours in a humidified atmosphere with 5% CO2 prior to treatment with various concentrations (three fold serial dilution, 12 points) of test compounds. The A375P cell viability was assessed by the conventional 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. MTT assays were carried out with CellTiter 96® (Promega) according to the manufacturer's instructions. The absorbance at 590 nm was recorded using EnVision2103 (PerkinElmer; Boston, MA, US). The IC50 was calculated using GraphPad Prism 4.0 softwere.
3-Chloro-5-methoxybenzoic acid (2). A mixture of 3,5-dichlorobenzoic acid (1, 1.0 g, 5.2 mmol) and NaOMe (3.5 mL, 25 wt% solution in methanol, 16.2 mmol) in HMPA (2.0 mL) was heated at 120 o C for 15 h. The mixture was poured into ice-water and acidified with conc. HCl to give 3-chloro-5-methoxybenzoic acid (2, 1.2 g, 80%) as a precipitate which was collected by filtration and used in the next step without purification. 
4-[3-(3-Chloro-5-methoxyphenyl)-1H-pyrazol-4-yl]pyridine (5).
Compound (4, 1.0 g, 3.8 mmol) was added to DMF-DMA (5.14 mL, 38.2 mmol) and the mixture was stirred at room temperature for 18 h. The resulting solution was concentrated to dryness to furnish an oil which was used in the next step without any purification. To a portion of the oil from the previous step (0.137 g, 0.457 mmol) in EtOH (3.0 mL) was added hydrazine monohydrate (0.04 mL, 0.76 mmol) and the reaction was stirred overnight at room temperature. Water (5.0 mL) was added to the reaction mixture and the organics were extracted with ethyl acetate. The combined organic layer extracts were washed with brine and dried over MgSO4. After evaporation of the organic solvent, the residue was purified by column chromatography (silica gel, hexanes-ethyl acetate 1:1 v/v then switching to hexanes-ethyl acetate 1:5 v/v) to yield compound (5, 0.11 g, 81%). 
4-[3-(3-Chloro-5-methoxyphenyl)-1-(4-aminophenyl)-1H-pyrazol-4-yl]pyridine (7).
A mixture of compound (6, 0.5 g, 1.2 mmol) and Raney nickel (1.0 g) in 1,4-dioxane (5.0 mL) was stirred at room temperature under hydrogen atmosphere for 6 h. The mixture was filtered through celite and the filtrate was evaporated under reduced pressure to give compound (7, 0.5 g, 87%). C under N2 and the reaction mixture was stirred for 30 min. The mixture was warmed to room temperature and stirred for 1 h. The mixture was quenched with saturated aqueous NaHCO3. Ethyl acetate was added and the organic layer was separated. The aqueous layer was extracted with ethyl acetate. The combined organic layer extracts were washed with brine, dried with Na2SO4. After evaporation of the organic solvent, the residue was purified by short column chromatography (silica gel, hexanes-ethyl acetate 1:5 v/v) to yield compound IIa (45.0 mg, 92% 
